Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. - Wikidata - wikimedia - TriplyDB

Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.

Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.

http://www.wikidata.org/entity/Q36478280

about

Memory of infections: an emerging role for natural killer cells Immune Cells in Cancer Therapy and Drug Delivery The urgent need to recover MHC class I in cancers for effective immunotherapy The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer Alloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive Immunotherapy IL-15-PI3K-AKT-mTOR: A Critical Pathway in the Life Journey of Natural Killer Cells Natural killer cell biology: an update and future directions Interleukin 12: still a promising candidate for tumor immunotherapy?The effect of radiation on the immune response to cancers Immunological memory within the innate immune system Insufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cells IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.NK cell-extrinsic IL-18 signaling is required for efficient NK-cell activation by vaccinia virus.Interleukin-18 produced by bone marrow-derived stromal cells supports T-cell acute leukaemia progression Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells.Intact IL-12 signaling is necessary for the generation of human natural killer cells with enhanced effector function after restimulation.IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells.NK cells and their ability to modulate T cells during virus infections Cytokine therapy reverses NK cell anergy in MHC-deficient tumors Mesenchymal stem cells expressing interleukin-18 suppress breast cancer cells in vitro.Human cytomegalovirus drives epigenetic imprinting of the IFNG locus in NKG2Chi natural killer cells.Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients Overexpression of IL-15 promotes tumor destruction via NK1.1+ cells in a spontaneous breast cancer model.Enhanced Control of Bladder-Associated Tumors Using Shrimp Anti-Lipopolysaccharide Factor (SALF) Antimicrobial Peptide as a Cancer Vaccine Adjuvant in Mice.Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.Natural Killer Cell Memory.IL-12/15/18-preactivated NK cells suppress GvHD in a mouse model of mismatched hematopoietic cell transplantation TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent.Unique Eomes(+) NK Cell Subsets Are Present in Uterus and Decidua During Early Pregnancy.Natural killer cells and antifungal host response.Human Cytokine-Induced Memory-Like Natural Killer Cells.Influenza Vaccination Generates Cytokine-Induced Memory-like NK Cells: Impact of Human Cytomegalovirus Infection.Tracking the fate of antigen-specific versus cytokine-activated natural killer cells after cytomegalovirus infection.The anti-tumor role of NK cells in vivo pre-activated and re-stimulated by interleukins in acute lymphoblastic leukemia.Natural killer cells: walking three paths down memory lane.Antitumor immune responses induced by ionizing irradiation and further immune stimulation.At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.

P2860

Q21131375-D6B620ED-BB31-4C88-8E05-51C96B9BB9E5 Q26747061-08F05000-719C-4141-B5D1-F0E3D41FF26F Q26770165-B3ED930E-39C8-427A-A1CC-E5BD399E7AF7 Q26774678-91558D91-392D-4114-9B4E-7303E64BBB4C Q26777209-9F4A5E8A-CB86-4642-AC91-82A7B0ACC103 Q26800159-56C5F49B-C42C-474E-8B32-2198BD6CEF21 Q26830512-92082841-A14A-4650-8F1C-6F51FBED71AF Q26861559-439C042E-0875-4712-B35F-BF78E75517BF Q26995372-DE7005AB-559F-4F9C-BF6E-001493C55221 Q27001211-2B86EA7B-BD4A-491D-987B-63B6BED3A8BC Q28068375-AB149F4B-6B47-4424-9B7C-AE07E227178E Q28251295-9EB964D5-F1AD-4142-80B2-6CD946655766 Q33700795-54B2F05D-0D8C-4F20-8469-D4754C096033 Q33703046-A4F6B47E-9880-4AB0-9504-6E2A51130CDA Q34195250-224E97EB-BBEC-452E-A7AF-B3EA84978E58 Q34372296-6860D595-0AC3-4ADF-B2F1-3B4AB0087EF6 Q34551199-C0FE6140-A747-45F0-96CE-E3B89B5B5185 Q34616985-5F44FABC-CCF5-4A96-AEC7-9ECDFC7C5DB4 Q34651540-19C6E285-373C-406A-B998-337373AAB59D Q34700499-8FEC693A-B334-4809-8F7A-6907BCB67808 Q35140125-707C1945-C419-4B8F-A8B9-0961122B795B Q35159519-2B667640-BF50-4D1E-8C94-54223B4303B0 Q35348821-41A9FE85-FBD2-41C5-95A7-3F2537F7F8F7 Q35575280-F0277AAA-CCD4-496E-97A7-ED7E36517BE1 Q35595605-C6B5B649-461A-4D93-AC2D-1AAE873A7C3F Q35657546-466B39D3-302F-4483-8D5E-D950AE14F84B Q35710332-35890567-94C0-4077-9D4E-0B0F44C5F6E0 Q36211144-AD92F1F1-2D91-460F-871B-5C88DCD5B9D1 Q36393953-E1488B38-0D34-4915-9533-C710596DB457 Q36515165-FED180A8-FBBE-4C5C-A118-B2B644417F1A Q36616920-BFD60045-7C67-4FE5-A331-EA6C1EF6FFC5 Q36694912-46AF7BDB-9748-4CCC-ACA7-3BA860131E95 Q36757854-5B9685E5-C413-42CF-BB6B-FFAFCEB34347 Q36830628-06D384F9-5664-4A9C-9E2F-CB72FCBCA82F Q37015056-5534B346-CD4C-42E7-A4A8-54087709BE7B Q37415250-AB1174D5-EC4C-4C3F-89E8-39B30E55380C Q37694772-1DE6D7AD-BF25-479F-B2FA-122B1C489264 Q38090202-DB6ED7FB-5C11-47A5-9761-9AFE53E57FE4 Q38139854-07859AD4-724C-4C7C-8318-12895737E4AC Q38149725-2F07D9B6-B132-46CD-8AD0-8D8FA2C4CF2D

P2860

Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.

http://www.wikidata.org/entity/Q36478280

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Sustained effector function of ...... ls against established tumors.

@ast

Sustained effector function of ...... ls against established tumors.

@en

type

label

Sustained effector function of ...... ls against established tumors.

@ast

Sustained effector function of ...... ls against established tumors.

@en

prefLabel

Sustained effector function of ...... ls against established tumors.

@ast

Sustained effector function of ...... ls against established tumors.

@en

P1433

Q36478280-64CE0CE8-2224-47E3-A9DE-CA012E264196

P1476

Q36478280-5DE30317-E624-4425-AC4A-DDEF69EE1362

P2093

Q36478280-3EEDAA09-9344-4F2A-9188-334E4768BDA3

Q36478280-60B5855A-FDD3-4ACD-A7FC-92C67E1731BE

Q36478280-9BA3AE8D-5ABE-4487-B235-288E9F7999C5

Q36478280-FBBE8108-923C-42D0-888B-87A4D1A5C3EF

P2860

Q36478280-09FA4020-5721-4A72-90AC-FCD97ED186E5

Q36478280-0ED656DF-0701-4D48-A6C0-F5D4609E598A

Q36478280-10C86E8D-6765-4FD6-9D5E-F56457BBE95A

Q36478280-1284B4D7-3FA9-4056-AE98-BA41C25EE730

Q36478280-185AC974-DE10-47BD-8E61-1D8C1CDF811B

Q36478280-1A7EF290-8FAE-495C-8C5C-CD291ECE4C2A

Q36478280-1CD73633-2F9C-4E7D-917A-273B3FF580FA

Q36478280-20032E97-4CAB-4FE2-9804-FA6B063DA8A0

Q36478280-25073F04-E12A-45BD-B0B9-635F55822470

Q36478280-28A9B176-27FF-42FC-A9BE-79EE2D6A911D

P304

Q36478280-698BF751-1FDC-42A5-B534-09FDE99FF7A6

P31

Q36478280-BCB21D04-8B00-4729-A69E-EAB37F4E9FE6

P356

Q36478280-EDAAA6F3-A0E9-4B40-BCFE-8F834586D97D

P407

Q36478280-9BBDC883-0A6F-40F4-9BF1-7DA49700548D

P433

Q36478280-1BD9992E-C3C1-4B5A-84CC-29CB0A4D3CBA

P478

Q36478280-99C78FDD-FC62-4A01-86C7-A3A6C14B61C1

P50

Q36478280-1B9EA7F3-EA9B-4249-8A71-296D24514A80

P577

Q36478280-6AF8A23C-62CF-4882-AEC1-982D29D555B1

P5875

Q36478280-EF8C418B-AD24-4AC4-BC45-14AF11DB8682

P698

Q36478280-92BF7AEB-3BD8-4C59-A4DE-8EC6BD822A39

P932

Q36478280-BADF150B-0191-4DF7-896D-784687D21049

P356

P1433

Journal of Experimental Medicine

P1476

Sustained effector function of ...... lls against established tumors

@en

P2093

Adelheid Cerwenka

http://www.w3.org/2001/XMLSchema#string

Jing Ni

http://www.w3.org/2001/XMLSchema#string

Matthias Miller

http://www.w3.org/2001/XMLSchema#string

Natalio Garbi

http://www.w3.org/2001/XMLSchema#string

P2860

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

Adoptive immunotherapy for cancer: building on success

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions

Functions of natural killer cells

Innate or adaptive immunity? The example of natural killer cells

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

P304

2351-2365

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20120944

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

209

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233840436

http://www.w3.org/2001/XMLSchema#string

P698

23209317

http://www.w3.org/2001/XMLSchema#string

P932

3526364

http://www.w3.org/2001/XMLSchema#string